SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

EIKON THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

282564103

(CUSIP Number)

02/04/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

282564103

Names of Reporting Persons

PERLMUTTER ROGER M

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,893,171.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,893,171.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,893,171.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.2 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: The shares listed in Rows 5 and 7 consist of (i) (a) 1,190,999 shares of common stock, $0.0001 par value per share (the Common Stock) of Eikon Therapeutics, Inc. (the Issuer) and (b) options to purchase 1,417,315 shares of Common Stock, exercisable within 60 days of March 31, 2026, held directly by Dr. Roger M. Perlmutter, and (ii) 284,857 shares of Common Stock held directly by Perlmutter Consulting, Inc. Dr. Perlmutter is the president and sole shareholder of Perlmutter Consulting, Inc. and may be deemed to have sole power to vote and to dispose its shares. The percentage in Row 11 is based on 54,138,555 shares of Common Stock outstanding on March 17, 2026 as reported by the Issuer on its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2026.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

EIKON THERAPEUTICS, INC.

(b)

Address of issuer's principal executive offices:

230 HARRIET TUBMAN WAY, MILLBRAE, CALIFORNIA, 94030

Item 2.

(a)

Name of person filing:

This Schedule is filed by Roger M. Perlmutter.

(b)

Address or principal business office or, if none, residence:

230 Harriet Tubman Way, Millbrae CA 94030

(c)

Citizenship:

See Row 4 of the cover page.

(d)

Title of class of securities:

Common Stock, $0.0001 par value per share

(e)

CUSIP Number(s):

282564103

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

See Row 9 of the cover page.

(b)

Percent of class:

See Row 11 of the cover page.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Row 5 of the cover page.

(ii) Shared power to vote or to direct the vote:

See Row 6 of the cover page.

(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of the cover page.

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of the cover page.

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PERLMUTTER ROGER M

Signature:	/s/ Roger M. Perlmutter
Name/Title:	Roger M. Perlmutter
Date:	05/13/2026

SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.